Inogen was founded in 2001 to improve quality of life and increase freedom and independence for oxygen therapy users, predominantly Chronic Obstructive Pulmonary Disease (COPD) patients. COPD is the fourth leading cause of death in the United States, and the only major disease with an ever increasing death rate. By 2020 COPD is predicted to become the third leading cause of death worldwide. COPD affects an estimated 30 million people in the US and over 100 million worldwide.
Supplemental oxygen has been proven to reduce the symptoms of the disease and extend life expectancy of patients with COPD. Despite the clear benefits of oxygen in extending life and maintaining health, many patients find it difficult to comply with therapy because currently available therapy devices inhibit their ability to lead an active life. Today's more active patient is refusing to be restricted in their lifestyle by being tethered to antiquated, stationary machines.